Vivek Subbiah,
Vivek Subbiah/LinkedIn

Vivek Subbiah: Targeting the Warburg Effect in Solid Tumors… Nearly a Decade in the Making

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

“On behalf of all the co-investigators, Delighted to share the publication of our Phase 1 trial results, nearly a decade in the making.

‘Phase 1a/b Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect in Solid Tumors’ is now published in AACR Journals Cancer Research Communications

Grateful to our collaborators, investigators, and the patients who made this possible.”

Title: Phase 1a/b Multi-Center Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients

Authors: Vivek Subbiah, Peter Yu, Rangaprasad Sarangarajan, Michael Kiebish, Leonardo Rodrigues, Gregory Miller, Viatcheslav Akmaev, Shen Luan, John McCook, Nikunj Tanna, Tracey Reilly, Emily Chen, Valerie Bussberg, Shobha Ravipaty, Vivek Vishnudas, Stephane Gesta, David Lucius, Can Bruce, Suwagmani Hazarika, Arianne Lyng, Allison Klotz, Vladimir Tolstikov, Janice Stevens, Victoria Chua, Elder Granger, Poornima Tekumalla, Ely Benaim, Vijay Modur, Marc Rudoltz, Paul Song, Scott Tagawa, Andrew Hendifer, Sant Chawla, Manish Shah, David Hong, Ralph Zinner, Niven Narain, Madappa Kundranda

Read the Full Article on AACR Journals Cancer Research Communications

Vivek Subbiah: Targeting the Warburg Effect in Solid Tumors... Nearly a Decade in the Making

More posts featuring Vivek Subbiah.